GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Study Explores Cost-Effectiveness of Home-Based Phototherapy for Treating Neonatal Jaundice

by GOAI
Share To

Recent research published in *Pediatric Research* examines the cost-effectiveness of home-based phototherapy as a treatment for neonatal jaundice. The study evaluates whether administering phototherapy at home, rather than in a hospital setting, could provide a more economical and accessible option for managing this common condition in newborns. Neonatal jaundice, which occurs due to elevated bilirubin levels, is typically treated with phototherapy under medical supervision in hospitals.

The study, led by researchers Pettersson and Ryen, investigates the financial implications and potential benefits of shifting this treatment to a home environment. Phototherapy has traditionally been limited to hospital care due to concerns about safety and efficacy outside clinical settings. However, the findings aim to address these concerns while exploring whether home-based care could reduce healthcare costs without compromising treatment outcomes. The research highlights an important shift in neonatal care practices that may influence future healthcare policies and approaches worldwide.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 3, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top